Covid 19 Research Clinical Trials by Shray Alag

	Name (Synonyms)	Correlation
drug4439	consultation Wiki	0.58
drug4318	XCEL-UMC-BETA Wiki	0.58
drug2616	Normal Saline Wiki	0.24

Name (Synonyms)

Correlation

drug4439

consultation Wiki

0.58

drug4318

XCEL-UMC-BETA Wiki

0.58

drug2616

Normal Saline Wiki

0.24

	Name (Synonyms)	Correlation
drug4168	Usual Care Wiki	0.19
drug274	Anakinra Wiki	0.19
drug2365	Methylprednisolone Wiki	0.15
drug4025	Tocilizumab Wiki	0.09
drug421	Azithromycin Wiki	0.09
drug2916	Placebo Wiki	0.02

Name (Synonyms)

Correlation

drug4168

Usual Care Wiki

0.19

drug274

Anakinra Wiki

0.19

drug2365

Methylprednisolone Wiki

0.15

drug4025

Tocilizumab Wiki

0.09

drug421

Azithromycin Wiki

0.09

drug2916

Placebo Wiki

0.02

	Name (Synonyms)	Correlation
D008171	Lung Diseases, NIH	0.12
D012140	Respiratory Tract Diseases NIH	0.11
D012127	Respiratory Distress Syndrome, Newborn NIH	0.10

Name (Synonyms)

Correlation

D008171

Lung Diseases, NIH

0.12

D012140

Respiratory Tract Diseases NIH

0.11

D012127

Respiratory Distress Syndrome, Newborn NIH

0.10

	Name (Synonyms)	Correlation
D055371	Acute Lung Injury NIH	0.10
D012141	Respiratory Tract Infections NIH	0.09
D012128	Respiratory Distress Syndrome, Adult NIH	0.09
D013577	Syndrome NIH	0.05
D011014	Pneumonia NIH	0.03

Name (Synonyms)

Correlation

D055371

Acute Lung Injury NIH

0.10

D012141

Respiratory Tract Infections NIH

0.09

D012128

Respiratory Distress Syndrome, Adult NIH

0.09

D013577

Syndrome NIH

0.05

D011014

Pneumonia NIH

0.03

	Name (Synonyms)	Correlation
HP:0002088	Abnormal lung morphology HPO	0.12
HP:0011947	Respiratory tract infection HPO	0.09
HP:0002090	Pneumonia HPO	0.03

Name (Synonyms)

Correlation

HP:0002088

Abnormal lung morphology HPO

0.12

HP:0011947

Respiratory tract infection HPO

0.09

HP:0002090

Pneumonia HPO

0.03

Clinical Trials

Navigate: Correlations HPO

There are 3 clinical trials

1 Phase 2, Randomized, Open-label Study to Compare Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID19 Pneumonia

In our center up to 25% of the hospitalized patients with COVID-19 progress and need an intensive care unit. It is urgent to find measures that can avoid this progression to severe stages of the disease. We hypothesize that the use of anti-inflammatory drugs used at the time they start hyperinflammation episodes could improve symptoms and prognosis of patients and prevent their progression sufficiently to avoid their need for be admitted to an Intensive Care Unit.

NCT04329650

Conditions

COVID-19

Interventions

Drug: Siltuximab
Drug: Methylprednisolone

MeSH:Pneumonia

HPO:Pneumonia

Primary Outcomes

Measure: Proportion of patients requiring ICU admission at any time within the study period.

Time: 29 days

Secondary Outcomes

Measure: Days of stay in the ICU during the study period.

Time: 29 days

Measure: Days until resolution of fever defined as body temperature (axillary ≤ 36.6 ° C, oral ≤ 37.2 ° C, or rectal or tympanic ≤ 37.8 ° C) for at least 48 hours, without administration of antipyretics or until hospital discharge.

Time: 29 days

Measure: Proportion of patients with a worsening requirement of supplemental oxygen at 29 days. days.

Time: 29 days

Measure: Days with hypoxemia (SpO2 <93% in ambient air or requiring oxygen supplemental or mechanical ventilation support) at 29 days.

Time: 29 days

Measure: Proportion of patients using mechanical ventilation at 29 days.

Time: 29 days

Measure: Days with use of mechanical ventilation at 29 days.

Time: 29 days

Measure: Days until the start of use of mechanical ventilation, non-invasive ventilation or use of high flow nasal cannula (if the patient have not previously required these interventions at the inclusion of the study) at 29 days.

Time: 29 days

Measure: Days of hospitalization among survivors at 29 days.

Time: 29 days

Measure: Mortality rate from any cause at 29 days.

Time: 29 days

Measure: Proportion of patients with serious adverse events at 29 days.

Time: 29 days

Measure: Proportion of patients with invasive bacterial or fungal infections clinically significant or opportunistic with grade 4 neutropenia (count neutrophil absolute <500 / mm3) at 29 days.

Time: 29 days

Measure: Proportion of patients with invasive bacterial or fungal infections clinically significant or opportunistic at 29 days.

Time: 29 days

Measure: Proportion of patients with grade 2 or higher adverse reactions related to the infusion of the sudy treatments at 29 days.

Time: 29 days

Measure: Proportion of patients with hypersensitivity reactions of grade 2 or higher related to the administration of the study treatments at 29 days.

Time: 29 days

Measure: Proportion of patients with gastrointestinal perforation at 29 days.

Time: 29 days

Measure: Proportion of patients with secondary severe infections confirmed by laboratory or worsening of existing infections at 29 days.

Time: 29 days

Measure: Changes from baseline in plasma leukocyte levels at days 1, 3, 5, 7 and 9.

Time: Days 1, 3, 5, 7 and 9

Measure: Changes from baseline in plasma hemoglobin levels at days 1, 3, 5, 7 and 9.

Time: Days 1, 3, 5, 7 and 9

Measure: Changes from baseline in plasma platelet at days 1, 3, 5, 7 and 9.

Time: Days 1, 3, 5, 7 and 9

Measure: Changes from baseline in plasma creatinine levels at days 1, 3, 5, 7 and 9.

Time: Days 1, 3, 5, 7 and 9

Measure: Changes from baseline in plasma total bilirubin levels at days 1, 3, 5, 7 and 9.

Time: Days 1, 3, 5, 7 and 9

Measure: Proportion of patients with ALT≥ 3 times ULN (for patients with initial values normal) or> 3 times ULN AND at least 2 times more than the initial value (for patients with abnormal initial values) at days 1, 3, 5, 7 and 9.

Time: Days 1, 3, 5, 7 and 9

Measure: Changes from baseline in plasma biomarkers (PCR, lymphocytes, ferritin, d-dimer and LDH) at days 1, 3, 5, 7 and 9.

Time: Days 1, 3, 5, 7 and 9

Measure: Changes from baseline in chest Rx at days 1, 3 and 5.

Time: Days 1, 3 and 5

2 A Prospective, Randomized, Factorial Design, Interventional Study to Compare the Safety and Efficacy of Combinations of Blockade of Interleukin-6 Pathway and Interleukin-1 Pathway to Best Standard of Care in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure and Systemic Cytokine Release Syndrome

The purpose of this study is to test the safety and effectiveness of individually or simultaneously blocking IL-6 and IL-1 versus standard of care on blood oxygenation and systemic cytokine release syndrome in patients with COVID-19 coronavirus infection and acute hypoxic respiratory failure and systemic cytokine release syndrome

NCT04330638

Conditions

COVID-19

Interventions

Other: Usual Care
Drug: Anakinra
Drug: Siltuximab
Drug: Tocilizumab

Primary Outcomes

Description: defined as the time from randomization to either an improvement of two points on a six-category ordinal scale or discharge from the hospital: Death Hospitalized, on invasive mechanical ventilation or ECMO; Hospitalized, on non-invasive ventilation or high flow oxygen devices; Hospitalized, requiring supplemental oxygen Hospitalized, not requiring supplemental oxygen Not hospitalized

Measure: Time to Clinical Improvement

Time: at day 15

Secondary Outcomes

Description: defined as independece from supplemental oxygen

Measure: Time to improvement in oxygenation

Time: during hospital admission (up to 28 days)

Description: defined by Pa02/FiO2 ratio while breading room air

Measure: Mean change in oxygenation

Time: day 1, day 15 or hospital discharge, whichever is first

Measure: Number of days with hypoxia

Time: during hospital admission (up to 28 days)

Measure: Number of days of supplemental oxygen use

Time: during hospital admission (up to 28 days)

Measure: Time to absence fever for more than 48h without antipyretics

Time: during hospital admission (up to 28 days)

Measure: Number of days with fever

Time: during hospital admission (up to 28 days)

Measure: Time to halving of CRP levels compared to peak value during trial

Time: during hospital admission (up to 28 days)

Measure: Time to halving of ferritin levels compared to peak value during trial

Time: during hospital admission (up to 28 days)

Measure: Incidence of AEs (Adverse Events)

Time: during hospital admission (up to 28 days)

Measure: Incidence of SAEs (Serious Adverse Events)

Time: during hospital admission (up to 28 days)

Measure: Duration of hospital stay

Time: during hospital admission (up to 28 days)

Measure: Duration of hospital stay in survivors

Time: during hospital admission (up to 28 days)

Description: SOFA score: 0 (best) - 24 (worse)

Measure: Mean change of SOFA score (Sequential Organ Failure Assessment) between day 1 and day 7

Time: Day 1, day 7or hospital discharge, whichever is first

Description: SOFA score: 0 (best) - 24 (worse)

Measure: Mean change of SOFA score between day 1 and day 15

Time: day 1, day 15 or hospital discharge, whichever is first

Description: 6-point ordinal scale: Death Hospitalized, on invasive mechanical ventilation or ECMO; Hospitalized, on non-invasive ventilation or high flow oxygen devices; Hospitalized, requiring supplemental oxygen Hospitalized, not requiring supplemental oxygen Not hospitalized

Measure: Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-1

Time: at day 15 or hospital discharge, whichever is first

Measure: Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-6

Time: at day 15 or hospital discharge, whichever is first

Measure: Incidence of nosocomial bacterial or invasive fungal infection

Time: during hospital admission (up to 28 days)

Description: defined by Hs (Hemophagocytic Syndrome) score

Measure: incidence of secondary haemophagocytic lymphohistiocytosis

Time: during hospital admission (up to 28 days)

Description: defined by Hs score

Measure: Incidence of secondary haemophagocytic lymphohistiocytosisscore in relation to serum IL-1

Time: during hospital admission (up to 28 days)

Description: defined by Hs score

Measure: Incidence of secondary haemophagocytic lymphohistiocytosis in relation to serum IL-6

Time: during hospital admission (up to 28 days)

Measure: Time to first use of high-flow oxygen devices, non-invasive or invasive mechanical ventilation in non-ventilated patients

Time: during hospital admission (up to 28 days)

Measure: Time to first use of salvage systemic steroids in ventilated patients

Time: during hospital admission (up to 28 days)

Measure: Number of ventilator free days

Time: during hospital admission (up to 28 days)

Measure: Duration of mechanical ventilation in ventilated patients

Time: during hospital admission (up to 28 days)

Measure: Duration of ICU stay in patients that enrolled in trial while already on invasive or non-invasive mechanical ventilation

Time: during hospital admission (up to 28 days)

Measure: Time to progression to ARDS in ventilated patients, according to the adapted Berlin criteria

Time: during hospital admission (up to 28 days)

Measure: Time to progression to ARDS in ventilated patients according to IL-1

Time: during hospital admission (up to 28 days)

Measure: Time to progression to ARDS in ventilated patients according to IL-6

Time: during hospital admission (up to 28 days)

Measure: All-cause mortality rate (excluding group that entered during ventilation)

Time: during hospital admission (up to 28 days)

Measure: Percentage of patients in clinical status on 6-point Ordinal Scale

Time: at 10-20 weeks follow-up

Measure: Incidence of lung function abnormalities

Time: at 10-20 weeks follow-up

Measure: Incidence of lung fibrosis on chest CT scan

Time: at 10-20 weeks follow-up

Measure: All-cause mortality rate

Time: at 10-20 weeks follow-up

3 A Study Comparing the Efficacy and Safety of Standard of Care With or Without Siltuximab in Selected Hospitalized Patients With Viral Acute Respiratory Distress Syndrome (SILVAR)

This study will evaluate the efficacy and safety of siltuximab compared with normal saline in combination with standard of care (SOC) in selected hospitalized patients with COVID-19 previously treated with corticosteroids or another respiratory virus infection associated with acute respiratory distress syndrome (ARDS) and elevated C-reactive protein (CRP) levels.

NCT04616586

Conditions

Acute Respiratory Distress Syndrome
Lung Diseases
Pneumonia
Respiratory Tract Infections
Respiratory Tract Disease

Interventions

Drug: Siltuximab
Other: Normal Saline

MeSH:Respiratory Tract Infections Lung Diseases Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lung Injury Respiratory Tract Diseases

HPO:Abnormal lung morphology Respiratory tract infection

Primary Outcomes

Description: 28-day all-cause mortality

Measure: 28-day all-cause mortality

Time: Day 28

Secondary Outcomes

Description: Time to 7-category ordinal scale of clinical status improvement (T7COSCSI)

Measure: Time to 7-category ordinal scale of clinical status improvement (T7COSCSI)

Time: Up to 60 days

Description: Ventilator-free days (VFDs) within 28 days

Measure: Ventilator-free days (VFDs) within 28 days

Time: Up to 28 days

Description: Organ failure-free days (OFFD)

Measure: Organ failure-free days (OFFD)

Time: Up to 60 days

Description: Intensive care unit length of stay (ICU LOS)

Measure: Intensive care unit length of stay (ICU LOS)

Time: Up to 60 days

Description: Hospital length of stay (HLOS)

Measure: Hospital length of stay (HLOS)

Time: Up to 60 days

Description: In-hospital all-cause mortality (IHACM)

Measure: In-hospital all-cause mortality (IHACM)

Time: Up to 60 days

Description: 60-day all-cause mortality (60DACM)

Measure: 60-day all-cause mortality (60DACM)

Time: Up to 60 days

Description: Time to oxygenation improvement (TOI)

Measure: Time to oxygenation improvement (TOI)

Time: Up to 60 days

Description: Duration of supplemental oxygen (DSO)

Measure: Duration of supplemental oxygen (DSO)

Time: Up to 60 days

Description: Chest radiographic improvement (CRI)

Measure: Chest radiographic improvement (CRI)

Time: Up to 60 days

Description: Time to National Early Warning Score 2 improvement (TNEWS2I)

Measure: Time to National Early Warning Score 2 improvement (TNEWS2I)

Time: Up to 60 days

Description: Treatment-emergent adverse events (TEAEs)

Measure: Treatment-emergent adverse events (TEAEs)

Time: Up to 60 days

Description: Plasma siltuximab concentrations (PSCs)

Measure: Plasma siltuximab concentrations (PSCs)

Time: Up to 60 days

Description: Anti-siltuximab antibodies (ASA)

Measure: Anti-siltuximab antibodies (ASA)

Time: Up to 60 days

Related HPO nodes (Using clinical trials)

HP:0002088: Abnormal lung morphology

HP:0002090: Pneumonia

Genes 272

TBX20 DCLRE1C ZIC2 HLA-DQA1 GAS8 GRHL3 DNAI2 SFTPC CARD11 DNAJC21 CD81 NODAL PGM3 IL2RG GNPTAB ORC6 SFTPA2 CD247 NTRK1 TNFRSF13C SIX3 ACTA1 MUC5B LAMA3 IL2RG DNMT3B MED25 CHD7 TNFRSF13C EGFR ZBTB24 CACNA1C CYBB RNF125 NFKB1 CITED2 SMARCD2 SLC25A24 BLNK LRBA IRF8 DISP1 GAS1 KIAA0586 FOXH1 SFTPB CFTR KMT2D MAN2B1 LAMC2 P4HTM MASP2 CR2 CREBBP COL11A2 AFF4 ADA ICOS RAG1 FCGR2A CD3D SIX3 PRKCD DLL1 RANBP2 SIX3 TDGF1 PMM2 IL21R GATA4 WAS LTBP3 CFB KCNJ6 FOXH1 SGCG RNU4ATAC CDON TAF1 SLC35C1 LEP CDON EPM2A KDM6A UBB GAS1 FBLN5 ACP5 MCIDAS TBC1D24 CD79B MAN2B1 MTHFD1 TIMM8A SLC35A1 DNAI1 RAG2 ZIC2 BTK IL7R CD3E AFF4 PIK3CD NODAL NBN FOXH1 EFEMP2 NCF1 NFIX OFD1 RNF168 RAG2 SHH RAC1 DISP1 CD19 PANK2 TNFRSF13C FGF8 FANCF GLI2 IGLL1 ALMS1 SBDS EP300 CASP8 BLM ICOS DISP1 TGIF1 CRLF1 ADA UNC119 PIGN FOXP3 FGF8 TDGF1 PTCH1 NCF2 CR2 TDGF1 IL2RG GLI2 FGF8 NIPBL RAG2 WDR1 SHH BTK ZAP70 GLI2 TK2 FGFR1 CREBBP IL2RG GAS1 STAT3 DDR2 TGIF1 DCLRE1C GBA CFAP410 ELANE LAMB3 CDON IL7R MS4A1 NFKB2 STAG2 CD19 EXTL3 PTCH1 SIX3 TCIRG1 TBX20 PAFAH1B1 FOXH1 SAMD9 TNFRSF13B TGIF1 RAG1 ALMS1 NKX2-5 ZIC2 SP110 CD55 CYBA ACTC1 NFKB2 PEPD PNP PKHD1 FGF8 CYBC1 ACP5 TNFRSF11A CSPP1 WDR19 SHH DZIP1L TDGF1 DCLRE1C TLL1 JAK3 DLL1 STAG2 SHH NODAL POLA1 NOS1 TGIF1 PTCH1 ZIC2 ASAH1 TBCD CXCR4 RAC2 FGFR1 GAS1 EFL1 FMO3 HLA-DQB1 RYR1 SRP54 RAG1 BTK ABCA3 ZAP70 CARD11 SETBP1 USB1 SELENON RMRP KNSTRN NADK2 TERT CDON NHLRC1 NKX2-1 PTPRC GATA6 ICOS OSTM1 NODAL GFI1 ACADVL DLL1 PTCH1 TGFB1 TNFRSF13B KPTN TNFSF12 GLI2 ADA JAK3 LIG4 COL11A2 ODAD1 PLOD1 MYH6 DLL1 IFNGR1 SRP54 TNFSF12 IGHM RNU4ATAC SFTPC DOCK8 NBN FOXN1 DISP1 SMC1A

Protein Mutations 6

A2063G G551D K55R L460D R287Q S1009A

SNP 0

HP:0011947: Respiratory tract infection

Genes 785

SMARCA4 TBC1D24 SNX10 SLC1A4 GRHL3 CFAP298 RSPH4A CARD11 CD3E COG4 PGM3 ECM1 GNPTAB LIMK1 CD247 NTRK1 ZBTB24 MANBA CLEC7A IL2RG TARS1 DNAAF2 NSD2 DNAJB13 DNAAF3 EXOSC9 NELFA EDARADD STING1 MAP3K20 HLA-DPB1 OFD1 SMARCD2 ABCA12 SCNN1G SLC25A24 BLNK GAS2L2 TYK2 HELLS FOXH1 DNAAF6 INPPL1 OCRL GTF2E2 MASP2 COL11A2 MYO5A FCGR2A PRKCD RANBP2 IL21R GATA4 TSC2 LTBP3 CYBA SPINK5 CTLA4 KCNJ6 FOXH1 NAGLU GUSB SHROOM4 LIPN RNU4ATAC TPM3 HERC2 EPG5 GAS1 FBLN5 NRAS ACP5 MCIDAS MAN2B1 TIMM8A COL13A1 PTPN22 SLC35A1 SLC46A1 HGSNAT LYST ZNF341 XIAP LRRC56 IGH NODAL LETM1 TRIP4 EFEMP2 NCF1 MCM4 SFTPC RSPH4A IL2RB RAG2 RAC1 DISP1 WRAP53 PANK2 TNFRSF13C ARID2 SBDS NPAP1 ACTA1 BLM CD40LG ICOS CCDC103 SNORD116-1 FOXP3 TDGF1 IL6R CIITA GLI2 FGF8 DNAJB13 CCDC39 IDUA GATA4 NOP10 GNPTAB TBX6 MKRN3 SNORD115-1 ELANE SMN1 KIF20A PGM3 PEX13 CDON IL7R SCNN1A STAG2 PLEC FLI1 SIX3 TCIRG1 ZNHIT3 LAMA2 CYP4F22 DNAAF4 FAT4 ZIC2 CSF2RB CD55 NFKB2 PEPD TNFRSF13B FGF8 STK36 RFX5 RYR1 SHH DCLRE1C SLC25A22 TLL1 AP3D1 NODAL ZMYND10 NOS1 TPM2 TRIP11 ZIC2 CTCF RAC2 CTLA4 PLP1 GAS1 EFL1 FMO3 RYR1 CIITA DLL3 PRTN3 ABCA3 AGA PCNT RSPH1 ZAP70 NDN NHLRC1 DNAH1 SCNN1G ACADVL DCTN4 PTCH1 DKC1 GMNN TNFRSF13B GLI2 MCIDAS SCN11A ROR2 IVNS1ABP ODAD1 MESP2 SLC12A6 MGP CFAP300 RSPH9 UMPS KRAS SFTPC COL13A1 SNRPN GAS8 CACNA1B AK2 INPPL1 CHAT CCDC40 IL2RG CD3G TASP1 SLC18A3 SCNN1G KAT6B STAT1 ACTA1 MUC5B SMN1 TAP1 MED25 CHD7 COG4 SULT2B1 GBA SPEF2 SDR9C7 CFI IDUA FUCA1 SAMD9L FLNC NCF4 LRBA DRC1 RFXAP KIAA0586 DNAH5 DOCK8 MAN2B1 ATM LAMC2 TRAF3IP2 CR2 GALNS TAP2 AFF4 UNG DNAAF4 RFC2 NCF1 CD3D RELB ODAD4 TDGF1 PMM2 RUNX2 SGSH WAS IL17F IL6ST IRAK4 LRRC8A TAPBP CCNO PLCG2 HK1 MYL2 LEP ERCC3 IGLL1 EPM2A CCDC65 CD79B FLNA XIAP CYBB CD3E AFF4 MESP2 POLE FOXH1 HYDIN TNNI3 NFIX BCL10 RNF168 NEU1 NPM1 IGLL1 TGIF1 WAC ADA UNC119 PIGN GAA CD8A IKZF1 TSC2 LEPR ARSB COG6 VPS51 COLQ WDR1 BTK GAS1 TTC12 WASHC5 CD3D STAT3 CCDC40 ASAH1 DNAI2 LAMB3 NFKB2 PTCH1 COL6A3 PAFAH1B1 FOXH1 MBTPS2 RYR1 TNFRSF13B TGIF1 CLCN7 SP110 COL6A1 TCTN3 SMARCC2 PNP GLUL PKHD1 ALPL ACP5 WDR19 TDGF1 TFRC MGP DLL1 SHH TGIF1 EHMT1 EP300 ITGA7 ERF DNMT3B FGFR1 HLA-DQB1 SPAG1 SRP54 UBE2A TINF2 CARD11 ARID1B SELENON RMRP WAS NEK10 MAPK1 GATA6 SCNN1B SYT2 USB1 DLL1 POLR3A PRPS1 RSPH1 TNFSF12 PIK3R1 IER3IP1 GSN NME8 LIG4 IL7R ALB COL11A2 TGFB1 DLL1 IFNGR1 LAMTOR2 DNAAF5 NXN PTPN22 TBX20 RAB3GAP2 ALOXE3 ZIC2 LRRC56 HLA-DQA1 KIF1A GAS8 PSAP DNAI2 NOTCH2 DPM2 CD81 NODAL DNAH9 TBC1D23 NFKB2 ORC6 SMARCB1 SIX3 LAMA3 DNAH5 ATP6V0A2 EGFR ZBTB24 LYST ODAD4 CACNA1C CYBB RNF125 DPF2 CITED2 GATA6 IRF8 DISP1 GAS1 ABCA12 ODAD3 DNAAF2 MECP2 BIRC3 SFTPB ELN CFTR SCNN1A KMT2D MDM4 IL17RA CCDC39 IL17RA FCGR3A VPS33A ODAD1 IKBKB RSPH3 CREBBP TNFSF11 SCNN1B AGA SCNN1A ADA RAG1 RAG1 TGM1 DLL1 SIX3 CARMIL2 GTF2I CCDC65 ARID1A CFB RAG2 SCNN1G SOX4 NECTIN1 ZMYND10 SGCG DNAAF6 CDON TAF1 IGHM LAMB2 LEP CD79A CFTR HPS6 CCBE1 PWAR1 RPGR VPS33A BTK SCNN1A IL7R EPG5 PIK3CD NBN HYDIN PSMB8 VAMP1 SDCCAG8 SHH RAC2 CD19 HLA-B GLI2 FLNA ALMS1 SCNN1B ITCH SPAG1 DISP1 DNAAF5 IDUA FGF8 MSN SMARCE1 BCR SERPINA1 PRPS1 NIPBL RAG2 ZAP70 TK2 FGFR1 CREBBP ALOX12B RFXANK IFIH1 GBA USP9X IKBKB MYOD1 CCNO TBCE GBA TSC1 PLCG2 G6PC3 MS4A1 CD19 EXTL3 GUSB DYNC2I2 NGLY1 SAMD9 NME8 TRAIP PYROXD1 SIK1 SLC26A2 RAG1 ALMS1 NKX2-5 IL21 FOXP1 LAMTOR2 ACTC1 FOXJ1 ARID1B SCNN1B CYBC1 CSPP1 SMARCD1 JAK3 STAG2 PCGF2 CXCR4 LEPR POLA1 PTCH1 RPGR ASAH1 ASAH1 RAG2 MYSM1 BTK DCLRE1C CFTR KNSTRN FOXJ1 PEPD TERT CDON TCF3 NKX2-1 ICOS DNAH11 OSTM1 ALG12 KATNIP TGFB1 KPTN ADA TPP2 MKRN3-AS1 SLC25A1 MYH6 HLA-DPA1 FBLN5 SRP54 TNFSF12 IGHM NEK10 RSPH3 TTC12 CRKL RASGRP1 SELENON DOCK8 GLI3 SMC1A DCLRE1C DNAL1 RIPK1 SFTPC CD79A TNNT2 DNAJC21 TSC1 CTSC USP9X SFTPA2 PIK3R1 TNFRSF13C NR2F2 CFTR ADNP DNMT3B TCIRG1 CFAP221 TNFRSF13C NFKBIA NFKB1 NEPRO SLC52A3 CLIP2 CRELD1 FCN3 NCF2 SIM1 BAZ1B P4HTM DNAAF3 GAS2L2 CCDC103 UGP2 GATA2 ICOS CDCA7 SIX3 JAGN1 CLCA4 STX1A MYH3 STAT3 DNAH11 LRRC6 SLC35C1 CDON IL17RC CD79B KDM6A UBB NHP2 NCF4 CCDC22 MAGEL2 TBC1D24 MTHFD1 MIR140 BLNK LCK NFE2L2 CSF2RA MYSM1 DNAI1 RAG2 ZIC2 HACD1 MPLKIP TLL1 COL6A2 OFD1 PARN SCN9A FGF8 MAGEL2 FANCF CORO1A PIK3R1 PRKDC CR2 EP300 PIK3CD CASP8 CRLF1 PTCH1 NCF2 SH3KBP1 CR2 DNAAF1 AGRN RFXANK TDGF1 IL2RA SOX11 IL2RG ATM ODAD3 CYBC1 SNAP25 SMPD1 TRPS1 SHH ELP1 GLI2 CHRM3 IL2RG PNP BACH2 CREBBP SH2D1A WIPF1 DDR2 CTC1 TGIF1 RFX5 DCLRE1C CFAP410 GTF2IRD1 SLC5A7 ERCC2 TERC ADAMTS3 TBX20 ODAD2 SLC29A3 MALT1 DSG1 TECPR2 IPW NGLY1 CYBA EP300 TNFRSF11A DZIP1L CD81 LRRC6 RTEL1 RAG1 DNAI1 MYPN NFKB1 ODAD2 TBCD ELANE CXCR4 PWRN1 TNFRSF1A FOXP1 MYO9A DNAAF1 TGFB1 RFXAP RAG1 SMPD1 CREBBP SETBP1 USB1 NADK2 MS4A1 CHAMP1 TERT NKX2-1 PTPRC SCN10A ELP1 POLR2A NODAL GFI1 PLG RNF113A TBL2 RSPH9 CFAP298 CD19 JAK3 AICDA GLB1 GTF2H5 NIPAL4 PLOD1 RNU4ATAC ITGA3 NBN GNS FOXN1 STAT1 DISP1 B2M

Protein Mutations 1

H275Y

SNP 0

Reports

Data processed on September 26, 2020.

An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

Drug Reports

MeSH Reports

HPO Reports

Report Sections

See All Reports

Siltuximab

Correlations computed by analyzing all clinical trials.

Correlated Drug Terms (9)

Correlated MeSH Terms (8)

Correlated HPO Terms (3)

Clinical Trials

1 Phase 2, Randomized, Open-label Study to Compare Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID19 Pneumonia Click for details

NCT04329650

Conditions

Interventions

MeSH:Pneumonia

HPO:Pneumonia

Primary Outcomes

Secondary Outcomes

NCT04330638

Conditions

Interventions

Primary Outcomes

Secondary Outcomes

3 A Study Comparing the Efficacy and Safety of Standard of Care With or Without Siltuximab in Selected Hospitalized Patients With Viral Acute Respiratory Distress Syndrome (SILVAR) Click for details

NCT04616586

Conditions

Interventions

MeSH:Respiratory Tract Infections Lung Diseases Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lung Injury Respiratory Tract Diseases

HPO:Abnormal lung morphology Respiratory tract infection

Primary Outcomes

Secondary Outcomes

Related HPO nodes (Using clinical trials)

Genes 1393

Protein Mutations 11

SNP 6

Genes 272

Protein Mutations 6

SNP 0

Genes 785

Protein Mutations 1

SNP 0

HPO

Related HPO nodes (Using clinical trials)

Genes 1393

Protein Mutations 11

SNP 6

Genes 272

Protein Mutations 6

SNP 0

Genes 785

Protein Mutations 1

SNP 0

Reports

1 Phase 2, Randomized, Open-label Study to Compare Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID19 Pneumonia

3 A Study Comparing the Efficacy and Safety of Standard of Care With or Without Siltuximab in Selected Hospitalized Patients With Viral Acute Respiratory Distress Syndrome (SILVAR)